News

Euclid Announces ABB Optical Group as Licensed Manufacturer and Distributor of Euclid Ortho-K Lenses

Euclid Vision Corporation (Euclid), a global leader in advanced orthokeratology (Ortho-K) lenses and proactive myopia management initiatives, is pleased to announce ABB Optical Group as a licensed manufacturer and distributor of the company’s Ortho-K lenses. ABB, known as the largest distributor of soft lenses in the United States, supplies nearly two-thirds of eye care professionals (ECPs) across the United States with optical products, services, and business solutions.

Given ABB’s reach, this new collaboration will provide greater access to Euclid’s clinically proven Ortho-K contact lenses to a much wider audience of ECPs. “The manufacturing and distribution arrangement capitalizes on the strengths of two leading companies in the specialty contact lens arena and manifests our shared vision of growing accessibility to myopia management products and services,” said Joseph Boorady, president and CEO, Euclid.

Euclid is the manufacturer of the Euclid Emerald® and Euclid MAX™ Ortho-K contact lenses, which are worn overnight and are designed to reshape the cornea, so patients wake up to clear vision. Euclid’s Ortho-K lenses have a unique design that yields an 87% first fit success¹ without requiring a trial set. ABB is well-equipped to support the manufacturing of Euclid’s lenses with their decades of gas permeable (GP) and custom soft lens manufacturing and specialty vision products distribution expertise.

“We are excited to work with Euclid and expand our licensed manufacturing, distribution, and myopia management product offerings with the addition of Euclid MAX lenses, a next generation Ortho-K product. Recognizing the continued rise of myopia as a serious eye-health issue, we are proud to bring an innovative Ortho-K design, which has the highest Dk of any US overnight Ortho-K brand, to our ABB customers.” said Aaron See, senior vice president of manufacturer partnerships, ABB.

Myopia is the leading cause of visual impairment in children worldwide, and its incidence and prevalence are on the rise, with estimates suggesting that more than half of the world’s population will be myopic by 2050.² “Increased accessibility to Euclid’s Ortho-K lenses means ABB’s customers can broaden their myopia management initiatives and help more myopic children at a critical time in the myopia epidemic,” said Nitin Jain, chief commercialization officer, Euclid. “This trend presents both a clinical challenge and practice management opportunity for ECPs poised to best serve their myopic patients. Together with ABB, we can provide easier access to myopia management products to help mitigate the extent of this epidemic,” added Jain.

Visit the Euclid MAX landing page to get started.

Recent News

04/24/2025

SSI Diagnostica Group Acquires Breath Test Maker Gulf Coast Scientific

Infectious disease diagnostics firm SSI Diagnostica Group said on Thursday that it has acquired Florida-based breath testing firm Gulf Coast Scientific for an undisclosed sum. Gulf Coast Scientific is a developer of urea breath tests for Helicobacter pylori infection, which is associated with conditions including chronic gastritis and gastric cancer. SSID Group said that the

04/23/2025

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories

04/22/2025

Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America

Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure. Marking a period of exceptional growth and momentum, Phlow has more than doubled in size and now employs over 90+ highly skilled scientists and professionals